Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000003586> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2000003586 endingPage "819" @default.
- W2000003586 startingPage "812" @default.
- W2000003586 abstract "To assess the response to encainide in patients with malignant arrhythmias, we treated 22 patients with recurrent ventricular tachycardia (VT) or fibrillation (VF) refractory to an average of 5.7 drugs. Thirteen patients (59%) showed a favorable in-hospital response, and 11 of 22 (50%) maintained a favorable antiarrhythmic response during a median follow-up of 13.5 months (range 0.3--25.5). Encainide was well tolerated. Six (46%) of 13 patients responded to intravenous encainide with suppression of VT by programmed ventricular stimulation or continuous monitoring; oral encainide has maintained arrhythmia control. In six of seven others, cycle length of VT was lengthened. Initial therapy with oral drug yielded five complete and two partial responses, assessed by monitoring, among nine other patients. Of three outpatient failures, only one was an inpatient responder. Proarrhythmic responses were also noted and included spontaneous increases in ectopy (three patients), easier induction of VT spontaneously or at programmed stimulation (three patients), facilitation of exercise VT (one patient), and syncope due to VT/VF (one patient). After intravenous therapy, plasma encainide concentration averaged 773 ng/ml (range 476--1,279, n = 4), with low or negligible metabolites. During chronic oral therapy, encainide concentrations were low and variable, averaging 67.5 ng/ml (less than 10--585; n = 23, 10 patients); metabolite levels were higher and less variable: O-demethyl encainide, mean 198 ng/ml (61--882); 3-methoxy-o-demethyl encainide, mean 128 ng/ml (39--379). Active metabolites(s) may thus be more important than parent drug during chronic therapy. In summary, encainide may provide successful therapy in approximately half of patients with malignant, refractory ventricular arrhythmias. Inpatient response predicts outpatient results. Encainide, like other antiarrhythmics, has proarrhythmic potential, suggesting a carefully monitored initial approach." @default.
- W2000003586 created "2016-06-24" @default.
- W2000003586 creator A5002592795 @default.
- W2000003586 creator A5017349008 @default.
- W2000003586 creator A5028606058 @default.
- W2000003586 creator A5050861046 @default.
- W2000003586 creator A5071011669 @default.
- W2000003586 date "1982-09-01" @default.
- W2000003586 modified "2023-09-23" @default.
- W2000003586 title "Response to Encainide of Refractory Ventricular Tachycardia" @default.
- W2000003586 doi "https://doi.org/10.1097/00005344-198209000-00018" @default.
- W2000003586 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6182414" @default.
- W2000003586 hasPublicationYear "1982" @default.
- W2000003586 type Work @default.
- W2000003586 sameAs 2000003586 @default.
- W2000003586 citedByCount "33" @default.
- W2000003586 crossrefType "journal-article" @default.
- W2000003586 hasAuthorship W2000003586A5002592795 @default.
- W2000003586 hasAuthorship W2000003586A5017349008 @default.
- W2000003586 hasAuthorship W2000003586A5028606058 @default.
- W2000003586 hasAuthorship W2000003586A5050861046 @default.
- W2000003586 hasAuthorship W2000003586A5071011669 @default.
- W2000003586 hasBestOaLocation W20000035861 @default.
- W2000003586 hasConcept C112705442 @default.
- W2000003586 hasConcept C121332964 @default.
- W2000003586 hasConcept C126322002 @default.
- W2000003586 hasConcept C142424586 @default.
- W2000003586 hasConcept C149151106 @default.
- W2000003586 hasConcept C164705383 @default.
- W2000003586 hasConcept C2776331378 @default.
- W2000003586 hasConcept C2778131192 @default.
- W2000003586 hasConcept C2780074459 @default.
- W2000003586 hasConcept C2780283014 @default.
- W2000003586 hasConcept C42219234 @default.
- W2000003586 hasConcept C71924100 @default.
- W2000003586 hasConcept C87355193 @default.
- W2000003586 hasConceptScore W2000003586C112705442 @default.
- W2000003586 hasConceptScore W2000003586C121332964 @default.
- W2000003586 hasConceptScore W2000003586C126322002 @default.
- W2000003586 hasConceptScore W2000003586C142424586 @default.
- W2000003586 hasConceptScore W2000003586C149151106 @default.
- W2000003586 hasConceptScore W2000003586C164705383 @default.
- W2000003586 hasConceptScore W2000003586C2776331378 @default.
- W2000003586 hasConceptScore W2000003586C2778131192 @default.
- W2000003586 hasConceptScore W2000003586C2780074459 @default.
- W2000003586 hasConceptScore W2000003586C2780283014 @default.
- W2000003586 hasConceptScore W2000003586C42219234 @default.
- W2000003586 hasConceptScore W2000003586C71924100 @default.
- W2000003586 hasConceptScore W2000003586C87355193 @default.
- W2000003586 hasIssue "5" @default.
- W2000003586 hasLocation W20000035861 @default.
- W2000003586 hasLocation W20000035862 @default.
- W2000003586 hasLocation W20000035863 @default.
- W2000003586 hasOpenAccess W2000003586 @default.
- W2000003586 hasPrimaryLocation W20000035861 @default.
- W2000003586 hasRelatedWork W156935181 @default.
- W2000003586 hasRelatedWork W1925989198 @default.
- W2000003586 hasRelatedWork W2069600595 @default.
- W2000003586 hasRelatedWork W2078400500 @default.
- W2000003586 hasRelatedWork W2085562752 @default.
- W2000003586 hasRelatedWork W2202497401 @default.
- W2000003586 hasRelatedWork W2385126491 @default.
- W2000003586 hasRelatedWork W3141700921 @default.
- W2000003586 hasRelatedWork W4323821335 @default.
- W2000003586 hasRelatedWork W2183687365 @default.
- W2000003586 hasVolume "4" @default.
- W2000003586 isParatext "false" @default.
- W2000003586 isRetracted "false" @default.
- W2000003586 magId "2000003586" @default.
- W2000003586 workType "article" @default.